{"id":"NCT04657003","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight","officialTitle":"Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-03-29","primaryCompletion":"2023-03-16","completion":"2023-04-10","firstPosted":"2020-12-07","resultsPosted":"2024-04-08","lastUpdate":"2024-04-08"},"enrollment":938,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes","Overweight","Obesity"],"interventions":[{"type":"DRUG","name":"Tirzepatide","otherNames":["LY3298176"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"10 milligrams (mg) Tirzepatide","type":"EXPERIMENTAL"},{"label":"15 mg Tirzepatide","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a study of tirzepatide in participants with type 2 diabetes who have obesity or are overweight. The main purpose is to learn more about how tirzepatide affects body weight. The study will last 79 weeks (22 visits).","primaryOutcome":{"measure":"Percent Change From Baseline in Body Weight","timeFrame":"Baseline, Week 72","effectByArm":[{"arm":"Placebo","deltaMin":-3.3,"sd":0.49},{"arm":"10 mg Tirzepatide","deltaMin":-13.4,"sd":0.48},{"arm":"15 mg Tirzepatide","deltaMin":-15.7,"sd":0.49}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":10},"locations":{"siteCount":75,"countries":["United States","Argentina","Brazil","India","Japan","Puerto Rico","Russia","Taiwan"]},"refs":{"pmids":["40512543","40120035","37385275"],"seeAlso":["https://trials.lillytrialguide.com/en-US/trial/6Lso9L1WmsU8ly9DkEFiaU"]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":315},"commonTop":["Diarrhoea","Nausea","Covid-19","Vomiting","Decreased appetite"]}}